Anti-vascular endothelial growth factor therapy in breast cancer: Game over?

Journal of Clinical Oncology

Volumn 33, Issue 2, 2015, Pages 133-135

  Sledge, George W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOCETAXEL; ERIBULIN; PACLITAXEL; PERTUZUMAB; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; AUTOPHAGY; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STEM CELL; CANCER THERAPY; CELL PROLIFERATION; COLORECTAL CANCER; DENDRITIC CELL; DISEASE FREE SURVIVAL; EDITORIAL; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; STOMATITIS; SUPPRESSOR CELL; TRIPLE NEGATIVE BREAST CANCER; UNITED STATES; BREAST NEOPLASMS; FEMALE; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL;

EID: 84920933145     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.1298     Document Type: Editorial

References (29)

1. Mackey JR, Ramos-Vazquez M, Lipatov O, et al: Primary results of ROSE/TRIO-12, a randomized, placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol 33:141-148, 2015.
2. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007.
3. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247, 2010.
4. Robert NJ, Dieras V, Glaspy J, et al: TIBBON-1: Tandomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260, 2011.
5. Sledge GW Jr: VEGF-targeting therapy for breast cancer. J Mammary Gland Biol Neoplasia 10:319-323, 2005.
6. Sledge GW Jr, Miller KD: Angiogenesis and antiangiogenic therapy. Curr Probl Cancer 26:1-60, 2002.
7. Sweeney CJ, Miller KD, Sissons SE, et al: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369-3372, 2001.
8. Lau DH, Xue L, Young LJ, et al: Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 14:31-36, 1999.
9. Miles DW, Diéras V, Cortés J, et al: First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: Pooled and subgroup analyses of data from 2447 patients. Ann Oncol 24:2773-2780, 2013.
10. Miller K, O'Neill A, Dang C, et al: Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol 32:5s, 2014 (suppl; abstr 500).
11. Slamon D, Swain S, Buyse M, et al: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2013, pp S1-03.
12. Cameron D, Brown J, Dent R, et al: Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial. Lancet Oncol 14:933-942, 2013.
13. Robert NJ, Saleh MN, Paul D, et al: Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 11:82-92, 2011.
14. Bergh J, Bondarenko IM, Lichinitser MR, et al: First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Tesults of a prospective, randomized phase III study. J Clin Oncol 30:921-929, 2012.
15. Crown JP, Diéras V, Staroslawska E, et al: Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 31:2870-2878, 2013.
16. Barrios CH, Liu MC, Lee SC, et al: Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121-131, 2010.
17. Fuchs CS, Tomasek J, Yong CJ, et al: Tamucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31-39, 2014.
18. Schneider BP, Sledge GW Jr: Anti-vascular endothelial growth factor therapy for breast cancer: Can we pick the winners? J Clin Oncol 29:2444-2447, 2011.
19. Schneider BP, Wang M, Radovich M, et al: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678, 2008.
20. Maru D, Venook AP, Ellis LM: Predictive biomarkers for bevacizumab: Are we there yet? Clin Cancer Res 19:2824-2827, 2013.
21. deHaas S, Delmar P, Bansal AT, et al: Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis [epub ahead of print on July 11, 2014].
22. Giuliano S, Pagès G: Mechanisms of resistance to anti-angiogenesis therapies. Biochimie 95:1110-1119, 2013.
23. Kerbel, RS: A cancer therapy resistant to resistance. Nature 390:335-336, 1997.
24. Allegra CJ, Yothers G, O'Connell MJ, et al: Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 31:359-364, 2013.
25. Bruix J, Takayama T, Mazzaferro V, et al: STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). J Clin Oncol 32:256s, 2014 (suppl; abstr 4006).
26. Voron T, Marcheteau E, Pernot S, et al: Control of the immune response by pro-angiogenic factors. Front Oncol 4:70, 2014.
27. Osada T, Chong G, Tansik R, et al: The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 57:1115-1124, 2008.
28. Jin Y, Chauhan SK, El Annan J, et al: A novel function for programmed death ligand-1 regulation of angiogenesis. Am J Pathol 178:1922-1929, 2011.
29. ClinicalTrials.gov: A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors. http://clinicaltrials.gov/show/NCT01633970.